Cite
Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
MLA
Massaro, Fulvio, et al. “Long‐term Results of the MCL01 Phase II Trial of Rituximab plus HyperCVAD Alternating with High‐dose Cytarabine and Methotrexate for the Initial Treatment of Patients with Mantle Cell Lymphoma.” British Journal of Haematology, vol. 192, no. 6, Mar. 2021, pp. 1011–14. EBSCOhost, https://doi.org/10.1111/bjh.16714.
APA
Massaro, F., Stepanishyna, Y., Manni, M., Luminari, S., Galimberti, S., Marcheselli, L., Visco, C., Tecchio, C., Stelitano, C., Angrilli, F., Petrini, M., Merli, F., & Federico, M. (2021). Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. British Journal of Haematology, 192(6), 1011–1014. https://doi.org/10.1111/bjh.16714
Chicago
Massaro, Fulvio, Yana Stepanishyna, Martina Manni, Stefano Luminari, Sara Galimberti, Luigi Marcheselli, Carlo Visco, et al. 2021. “Long‐term Results of the MCL01 Phase II Trial of Rituximab plus HyperCVAD Alternating with High‐dose Cytarabine and Methotrexate for the Initial Treatment of Patients with Mantle Cell Lymphoma.” British Journal of Haematology 192 (6): 1011–14. doi:10.1111/bjh.16714.